Viridian Therapeutics, Inc./DE Number of Operating Segments
Viridian Therapeutics, Inc./DE (VRDN) reported Number of Operating Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE number of operating segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Viridian Therapeutics, Inc./DE number of operating segments for the quarter ending 2025-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Viridian Therapeutics, Inc./DE number of operating segments for the quarter ending 2024-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Viridian Therapeutics, Inc./DE number of operating segments for the quarter ending 2023-03-31 was 1.00 segment, a 0.00% change year-over-year.
- Viridian Therapeutics, Inc./DE number of operating segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- Viridian Therapeutics, Inc./DE number of operating segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- Viridian Therapeutics, Inc./DE number of operating segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
- Viridian Therapeutics, Inc./DE number of operating segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-03 | |||
| 2024-09-30 | 1.00 segment 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 1.00 segment 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 1.00 segment 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-27 | |||
| 2023-09-30 | 1.00 segment 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 1.00 segment 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 1.00 segment 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-03-09 | |||
| 2022-09-30 | 1.00 segment 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 1.00 segment 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 1.00 segment 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-03-11 | |||
| 2021-09-30 | 1.00 segment 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | 1.00 segment 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 1.00 segment 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-03-26 | |||
| 2020-09-30 | 1.00 segment 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 1.00 segment 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | 1.00 segment 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 1.00 segment 10-K · filed 2020-03-13 | |||
| 2019-09-30 | 1.00 segment 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | 1.00 segment 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 1.00 segment 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 1.00 segment 10-K · filed 2019-03-14 | |||
| 2018-09-30 | 1.00 segment 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | 1.00 segment 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | 1.00 segment 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | 1.00 segment 10-K · filed 2018-03-15 | |||
| 2017-09-30 | 1.00 segment 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 1.00 segment 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | 1.00 segment 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |